How below-knee PAD treatment space is opening up after LIFE-BTK

Brian DeRubertis (Weill Cornell Medicine, New York, USA) was in the CX Studio during CX 2026 to analyse developments in the below-knee peripheral arterial disease (PAD) treatment landscape, dealing with  prevailing themes in the space, life after the landmark LIFE-BTK trial, how bioresorbable scaffolds have opened the space up, and what comes next. He also looks at the lack of a proven drug-coated balloon (DCB) below the knee and the ongoing conversation around paclitaxel-coated devices.